Literature DB >> 11498660

Angioneurotic edema.

L M Prisant1.   

Abstract

Angioneurotic edema is nonpitting edema involving the face, lips, tongue, larynx, and other locations. It may occur with use of angiotensin- converting enzyme inhibitors, vasopeptidase inhibitors, and, less frequently, angiotensin receptor blockers. Most episodes occur within the first 6 months of therapy. Predisposing factors for converting enzyme inhibitor angioedema include previous idiopathic angioedema, African American race, and transplant-related immunocompromise. Treatment is directed to preventing airway compromise. (c)2001 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498660      PMCID: PMC8101818          DOI: 10.1111/j.1524-6175.2001.00830.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  16 in total

1.  Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome.

Authors:  R Agah; V Bandi; K K Guntupalli
Journal:  Intensive Care Med       Date:  1997-07       Impact factor: 17.440

2.  Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients.

Authors:  J Abbosh; J A Anderson; A B Levine; W L Kupin
Journal:  Ann Allergy Asthma Immunol       Date:  1999-05       Impact factor: 6.347

3.  Recurrent angiotensin-converting enzyme inhibitor--associated angioedema.

Authors:  N J Brown; M Snowden; M R Griffin
Journal:  JAMA       Date:  1997-07-16       Impact factor: 56.272

4.  Plasma bradykinin in angio-oedema.

Authors:  J Nussberger; M Cugno; C Amstutz; M Cicardi; A Pellacani; A Agostoni
Journal:  Lancet       Date:  1998-06-06       Impact factor: 79.321

Review 5.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

6.  Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition.

Authors:  E E Slater; D D Merrill; H A Guess; P J Roylance; W D Cooper; W H Inman; P W Ewan
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

7.  Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors?

Authors:  T J Byrne; D D Douglas; M E Landis; J P Heppell
Journal:  Mayo Clin Proc       Date:  2000-11       Impact factor: 7.616

8.  Epidemiological study of angioedema and ACE inhibitors.

Authors:  G M Gabb; P Ryan; L M Wing; K A Hutchinson
Journal:  Aust N Z J Med       Date:  1996-12

9.  Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor.

Authors:  C Sigler; K Annis; K Cooper; H Haber; S Van deCarr
Journal:  Arch Dermatol       Date:  1997-08

10.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.

Authors:  N J Brown; W A Ray; M Snowden; M R Griffin
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

View more
  4 in total

Review 1.  Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.

Authors:  Reza Tabrizchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists.

Authors:  Joseph L Izzo; Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

3.  Antihypertensive pharmacobezoar.

Authors:  L Michael Prisant; Vernon C Spaulding
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

Review 4.  Obstructive sleep apnea syndrome.

Authors:  L Michael Prisant; Thomas A Dillard; Amy R Blanchard
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.